Summary Patients with cancer should benefit from COVID-19 vaccination. Some of the most advanced vaccine candidates are mRNAs encapsulated into lipid carriers, and small liposomes are expected to accumulate in tumour tissues through the enhanced and permeation retention effect. However, to what extent solid tumours could take up a significant part of the vaccine dose as well remains unknown. This calls for a careful evaluation of the efficacy of these promising mRNA COVID-19 vaccines administered as lipid carriers for patients with solid tumours, including a possible re-appraisal of the dosing for optimal protection of this specific and frail population.
All Keywords
【저자키워드】 Cancer immunotherapy, Health policy, 【초록키워드】 Efficacy, Cancer, vaccine dose, COVID-19 vaccination, mRNA, Patient, vaccine candidate, Dosing, Liposome, dose, mRNAs, Tumours, mRNA COVID-19 vaccine, tissue, solid tumour, carriers, appraisal, mRNA COVID-19 vaccines, Administered, benefit, permeation, the vaccine, expected, accumulate, lipid carrier, 【제목키워드】 COVID-19 vaccine, cancer patient,
【저자키워드】 Cancer immunotherapy, Health policy, 【초록키워드】 Efficacy, Cancer, vaccine dose, COVID-19 vaccination, mRNA, Patient, vaccine candidate, Dosing, Liposome, dose, mRNAs, Tumours, mRNA COVID-19 vaccine, tissue, solid tumour, carriers, appraisal, mRNA COVID-19 vaccines, Administered, benefit, permeation, the vaccine, expected, accumulate, lipid carrier, 【제목키워드】 COVID-19 vaccine, cancer patient,
요약 암 환자는 COVID-19 예방 접종의 혜택을 받아야 합니다. 가장 진보된 백신 후보 중 일부는 지질 운반체에 캡슐화된 mRNA이며, 작은 리포솜은 강화 및 투과 유지 효과를 통해 종양 조직에 축적될 것으로 예상됩니다. 그러나 고형 종양이 백신 용량의 상당 부분을 차지할 수 있는 정도는 아직 알려지지 않았습니다. 이것은 이 특정하고 허약한 집단에 대한 최적의 보호를 위한 투여의 가능한 재평가를 포함하여 고형 종양 환자를 위한 지질 운반체로 투여되는 이러한 유망한 mRNA COVID-19 백신의 효능에 대한 신중한 평가를 요구합니다.